Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

BACKGROUND: ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in patients with previously treated locally advanced/unresectable or metastatic urothelial carcinoma (UC). METHODS: Patients with UC were enrolled independent of tumor homologous recombination deficiency (HRD) status...

Descripción completa

Detalles Bibliográficos
Autores principales: Grivas, P., Loriot, Y., Morales-Barrera, R., Teo, M. Y., Zakharia, Y., Feyerabend, S., Vogelzang, N. J., Grande, E., Adra, N., Alva, A., Necchi, A., Rodriguez-Vida, A., Gupta, S., Josephs, D. H., Srinivas, S., Wride, K., Thomas, D., Simmons, A., Loehr, A., Dusek, R. L., Nepert, D., Chowdhury, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147008/
https://www.ncbi.nlm.nih.gov/pubmed/34030643
http://dx.doi.org/10.1186/s12885-021-08085-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147008/
https://www.ncbi.nlm.nih.gov/pubmed/34030643
http://dx.doi.org/10.1186/s12885-021-08085-z

Ejemplares similares